Last reviewed · How we verify
NCT06368687: TRANPAS
TRANPAS - TReating Anorexia Nervosa Plus Autism Spectrum
NA trial testing Anorexia nervosa plus autism in Anorexia Nervosa in 10 participants. Not yet recruiting.
31 December 2026
Quick facts
| Lead sponsor | Göteborg University |
|---|---|
| Phase | NA |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 10 |
| Start date | 15 August 2025 |
| Primary completion | 31 December 2026 |
| Estimated completion | 31 December 2026 |
Drugs / interventions tested
- Anorexia nervosa plus autism
Conditions studied
- Anorexia Nervosa — all drugs for Anorexia Nervosa →
- Autism Spectrum Disorder — all drugs for Autism Spectrum Disorder →
Sponsor
Göteborg University
Who can join
25 and older, any sex, with Anorexia Nervosa or Autism Spectrum Disorder. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
In a pilot study, the investigators will validate a so-called autism care location in an inpatient ward. The care location will be adapted for patients with anorexia nervosa (AN) and concurrent autism (AN+autism). In order to investigate the effect of a tailored care location for patients with AN + autism, the evaluation will include weight development and changes in nutritional intake, eating disorder and anxiety symptoms. The overall aim is to improve treatment for this specific AN subgroup, that otherwise has a worse prognosis regarding AN recovery.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06368687
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Anorexia Nervosa
Currently open trials in the same condition.
- NCT07169747 — Safety, Therapeutic Potential, and Mechanisms of Two Psilocybin Doses, Administered With Psychological Support in Young · Phase 2 · recruiting
- NCT07237607 — Developing an Artificial Intelligence (AI) Chatbot for Adolescents and Young Adults With Eating Disorders · NA · recruiting
- NCT07188155 — Adapting Exposure for Adolescent AN · NA · recruiting
- NCT07143981 — The Fecal Microbiome Transplant (FMT) Study for Anorexia Nervosa · recruiting
- NCT07311356 — Prognosis of Early-onset Anorexia Nervosa · recruiting
Other Göteborg University trials
Trials by the same sponsor.
- NCT07260604 — HIFEM for Incontinence After Menopause High-Intensity Focused Electromagnetic (HIFEM) · NA · not yet recruiting
- NCT07401420 — Life Sustaining Treatments in Critically Ill Children · not yet recruiting
- NCT07213245 — Metabolic Effects of Short-term Ultra-processed Food Intake (MEST-UPF) · NA · recruiting
- NCT07178405 — Effects of Meal Characteristics on Appetite · NA · completed
- NCT07172841 — Non-invasive Diagnostics of Shunt Obstruction in Adult Hydrocephalus · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06368687 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Göteborg University
- Last refreshed: 9 April 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06368687.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing